Two major new drugs, esomeprazole and Utilins, will be launched in this year

Qiu Yu, chairman and general manager of Laimei pharmaceutical, said at the online performance exchange meeting that the company is actively promoting the preparations for listing of esomeprazole and Utilins, and will be able to list within the year Laimei pharmaceutical is mainly engaged in anti infection products, specialty products and large infusion products Esomeprazole and Utilins are the two most important new drugs of the company at present, and are the main growth points of the company's future profits At the performance exchange meeting, when the above two new products can be put on the market to contribute to the company's earnings has become a core issue of concern to investors According to the public information, esomeprazole has been approved with the new GMP certification up to now and is in the process of product investment; Utilins has completed the on-site inspection of the new GMP certification and has not yet obtained the new GMP certificate It is worth mentioning that Qiu Yu also pointed out that esomeprazole has completed the price record work in Chongqing According to the inquiry of Chongqing price information network by DZH news, the trial sale price of 20mg * 7 esomeprazole enteric coated capsules of Laimei Pharmaceutical Co., Ltd is 88 yuan / box, and the price of a single capsule is about 12 yuan, which is equivalent to the "Nexium" of the original research drug AstraZeneca Esomeprazole is the latest generation of proton pump inhibitor The original drug "nexin" is AstraZeneca star product Its sales volume in 2010 and 2012 ranked first among the digestive prescription drugs in the United States Utilins is an adjuvant immunomodulator mainly used in the treatment of pulmonary and extrapulmonary tuberculosis Jinxing pharmaceutical, a subsidiary of Laimei pharmaceutical, is the only enterprise in China that has the approval of the drug.